Cofacalcium Solution for Injection

국가: 말레이시아

언어: 영어

출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

유효 성분:

CALCIUM GLUCONATE; MAGNESIUM HYPOPHOSPHITE

제공처:

Rhone Ma Malaysia Sdn Bhd

INN (International Name):

CALCIUM GLUCONATE; MAGNESIUM HYPOPHOSPHITE

패키지 단위:

500.00 mcg/mL

Manufactured by:

Dopharma France

제품 특성 요약

COFACALCIUM
SOLUTION FOR INJECTION
COMPOSITION/ML:
Calcium gluconate
280 mg
Magnesium hypophosphite 90 mg
PRODUCT DESCRIPTION: A clear colourless solution, odourless, acid
taste.
PHARMACODYNAMICS: The concentrated solute of calcium and magnesium
hypophosphite supplies the body in salts of calcium, magnesium
and phosphorous directly metabolisable. Their parenteral
administration allows to increase quickly the plasma concentration of
these ions
for the treatment of hypocalcaemia associated with hypomagnesia and/or
hypophosphatemia.
PHARMACOKINETICS: After parenteral administration, calcium, magnesium
and phosphorous are quickly distributed in the body. The binding
rate to plasma proteins is about 50% for calcium and from 30 to 50%
for magnesium. Calcium is mainly eliminated in faeces and magnesium
by urinary route.
INDICATION: Cattle, sheep, goats, horses, pigs, dogs and cats:
Preventive and curative treatment of hypocalcemia and/or hypomagnesia
and/or hypophosphatemia such as milk fever, parturient paresis,
grass tetany, eclampsia.
ROUTES OF ADMINISTRATION: Intramuscular, subcutaneous or slow
intravenous routes.
DOSAGE: 12.5 to 25 mg of calcium and 26.5 to 52.9 mg of magnesium
hypophosphite per kg of body weight per administration, equivalent
to 0.5 ml to 1 ml per kg of body weight by slow intravenous,
intramuscular or subcutaneous injection.
The administration may be repeated every 12 hours for 1 to 2
consecutive days if necessary.
CONTRAINDICATIONS: Do not use in animals having cardiac disorders.
WARNINGS AND PRECAUTIONS:
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The solution must be warmed to body temperature before administration.
Administer the product by slow intravenous administration, as a
infusion, and stop immediately if any adverse reactions appears.
When the product is administered by intramuscular or sub-cutaneous
route, divide the total dose into multiple injection sites in order to
minimize local reactions.
The use or reuse of this product may be subject t